Cisplatin-Induced Acute Kidney Injury and the Effect of Magnesium Supplementation cisplatin, acute kidney injury, AKI, magnesium
Conditions
Interventions
None listed
Sponsors
Iwakura Takamasa
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged 18 years or older with eGFR more than 15 ml/min who received their first cisplatin administration during the observation period
Exclusion criteria
Exclusion criteria: If the study participant or their proxy refuses or withdraws consent for the use of their samples or information in this study. Patients who do not have serum creatinine measurements available from one week before to the day of cisplatin administration. Patients with cisplatin orders on two or more consecutive days to exclude those receiving low-dose continuous cisplatin regimens. Patients with a baseline eGFR less than15 ml/min before cisplatin administration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This study aims to evaluate whether magnesium supplementation reduces kidney injury in patients receiving their first cisplatin administration. Specifically, it examines whether the change in eGFR differs depending on the presence or absence of magnesium supplementation. | — |
Secondary
| Measure | Time frame |
|---|---|
| The study will examine the incidence of acute kidney injury (AKI) based on the KDIGO clinical guidelines. AKI is defined as Stage 1 (an increase in serum creatinine of at least 0.3 mg/dL or 1.5 to 2 times the baseline level) and Stage 2 (an increase in serum creatinine at least twice the baseline level). The incidence rates of AKI (Stage 1 or higher and Stage 2 or higher) will be compared between two groups: patients with and without magnesium supplementation. | — |
Contacts
Public ContactTakamasa Iwakura
Hamamatsu University School of Medicine
Outcome results
None listed